Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 3/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.42 |
| ▸ | GPR52 | Q9Y2T5 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL6832372 | 0.99 | KDM4E (0.43) | KDM4EALDH1A1SMN1; SMN2MEN1KMT2A | |
| SCHEMBL9750739 | 0.78 | SIGMAR1 (0.52) | SMN1; SMN2 | |
| Hydrochloric Acid SCHEMBL11113593 | 0.77 | SIGMAR1 (0.51) | ALDH1A1SMN1; SMN2 | |
| SCHEMBL11128142 | 0.72 | SIGMAR1 (0.50) | ALDH1A1SMN1; SMN2MEN1KMT2A | |
| SCHEMBL6001346 | 0.71 | PARP1 (0.46) | KDM4EMEN1KMT2AGPR52 | |
| SCHEMBL6001349 | 0.71 | PARP1 (0.46) | KDM4EMEN1KMT2AGPR52 | |
| SCHEMBL14415619 | 0.71 | PARP1 (0.46) | KDM4EMEN1KMT2AGPR52 | |
| SCHEMBL30093277 | 0.70 | TAAR1 (0.56) | KDM4EALDH1A1SMN1; SMN2MEN1KMT2A | |
| SCHEMBL7324033 | 0.69 | ALDH1A1 (0.54) | KDM4EALDH1A1SMN1; SMN2 | |
| SCHEMBL11399881 | 0.69 | SIGMAR1 (0.47) | KDM4EALDH1A1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140335050-A1 | METHODS, COMPOSITIONS, AND KITS FOR THE TREATMENT OF CANCER | THE GENERAL HOSPITAL CORPORATION (US) | 2014-11-13 | — | — | US | disclosed |
| US-7268166-B2 | Compounds active at a novel site on receptor-operated calcium channels useful for treatment of neurological disorders and diseases | NPS PHARMACEUTICALS, INC. (US) | 2007-09-11 | — | — | US | disclosed |
| EP-1790337-A2 | Methods and compounds for treating depression and other disorders | NPS PHARMACEUTICALS, INC. (US) | 2007-05-30 | — | — | EP | disclosed |
| EP-1096926-B1 | METHODS AND COMPOUNDS FOR TREATING DEPRESSION | NPS PHARMA INC (US) | 2007-02-28 | — | — | EP | disclosed |
| EP-1096926-B1 | METHODS AND COMPOUNDS FOR TREATING DEPRESSION | NPS PHARMA INC (US) | 2007-02-28 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140335050-A1 | METHODS, COMPOSITIONS, AND KITS FOR THE TREATMENT OF CANCER | IL2RA, CD74, IL2 | KDM4E 4836/4885ALDH1A1 1004/4885SMN1; SMN2 4749/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.